RICHMOND, VA / ACCESSWIRE / April 20, 2017 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today that the Company management will present at the MedTech Strategist Innovation Summit scheduled for April 25-27, 2017, at The Shelbourne Hotel in Dublin, Ireland. To learn more about the MedTech Strategist Innovation Summit, please click here.
Event: MedTech Strategist Innovation Summit
Location: The Shelbourne Hotel in Dublin, Ireland
Date: April 26, 2017
Time: 9:05 AM DST (4:05 AM EDT)
Exactus CEO Philip Young will deliver a formal presentation and discuss recent business highlights and updates. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Tim Ryan at firstname.lastname@example.org or Robert Haag at email@example.com.
About The MedTech Strategist
The MedTech Strategist is an information and investment conferences provider focused exclusively on the underserved medtech market. It is led by managing partners and co-editors-in-chief David Cassak and Stephen Levin, along with a seasoned editorial team. The company launched The MedTech Strategist, a publication broadly covering the most important topics and trends in medical devices today, in September 2014. Featuring a wide range of editorial offerings - from interviews with industry leaders to stories on leading companies, profiles of groundbreaking start-ups, and analyses of dynamic clinical markets and technology trends - The MedTech Strategist explores how innovation plays out in all of its various forms - clinical, technological, business model, marketplace, and financing - in the global medical device arena.
About Exactus Inc.
Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money.
Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusinc.com.
This press release and any statements of representatives and partners of Exactus, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical trial described herein or the FDA's review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information:
Philip J. Young, President and CEO
Corporate Communications Contact:
Tim Ryan, EVP
Investor Relations Contact:
SOURCE: Exactus Inc.
Released April 20, 2017